In summary, targeting PLK1 lead to a striking tumour regression in three out of fpur CCND1-driven PDX models, while AKT1 and mTOR mutated PDX preferably responded to AKT1 and mTOR inhibitors. Here, PLK1 is linked to neoplasm.